Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Climb Bio (CLYM)
NASDAQ:CLYM
Holding CLYM?
Track your performance easily
CLYM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.35 - $11.55
Previous Close$3
Volume126.97K
Average Volume (3M)563.49K
Market Cap
$204.36M
Enterprise Value$8.38M
Total Cash (Recent Filing)$193.35M
Total Debt (Recent Filing)$58.00K
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding67,223,760
10 Day Avg. Volume309,341
30 Day Avg. Volume563,493
Standard Deviation0.32
R-Squared0.00281
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.95
Price to Sales (P/S)3310.26
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue126.94
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Climb Bio News
PremiumCompany Announcements
Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases
PremiumCompany Announcements
Climb Bio to Host Virtual Investor Event
Ownership Overview
8.54% Insiders
0.88% Mutual Funds
65.65% Other Institutional Investors
21.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLYM FAQ
What was Climb Bio’s price range in the past 12 months?
Climb Bio lowest stock price was $2.35 and its highest was $11.55 in the past 12 months.
What is Climb Bio’s market cap?
Currently, no data Available
When is Climb Bio’s upcoming earnings report date?
Climb Bio’s upcoming earnings report date is May 19, 2025 which is in 177 days.
How were Climb Bio’s earnings last quarter?
Climb Bio released its earnings results on Nov 12, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.13.
Is Climb Bio overvalued?
According to Wall Street analysts Climb Bio’s price is currently Overvalued.
Does Climb Bio pay dividends?
Climb Bio does not currently pay dividends.
What is Climb Bio’s EPS estimate?
Climb Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Climb Bio have?
Climb Bio has 67,223,760 shares outstanding.
What happened to Climb Bio’s price movement after its last earnings report?
Climb Bio reported an EPS of -$0.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.105%.
Which hedge fund is a major shareholder of Climb Bio?
Among the largest hedge funds holding Climb Bio’s share is RA Capital Management. It holds Climb Bio’s shares valued at 160M.
---
Climb Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CLYM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 105.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.04%
12-Months-Change
Fundamentals
Return on Equity
-42.08%
Trailing 12-Months
Asset Growth
97.10%
Trailing 12-Months
Company Description
Climb Bio
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
---
Technical Analysis
ATAI Life Sciences
―
Verrica Pharmaceuticals
―
Bioxcel Therapeutics
―
SELLAS Life Sciences Group
―
---